A phase I, randomized, placebo-controlled, double-blind, first in human, single ascending dose study of SJX-653 in healthy adult men
Latest Information Update: 28 Sep 2020
At a glance
- Drugs SJX-653 (Primary)
- Indications Hot flashes
- Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics; Proof of concept
- Sponsors Sojournix
Most Recent Events
- 21 Sep 2020 Results published in the Sojournix Media Release
- 18 Sep 2020 Results published in the Journal of Clinical Endocrinology and Metabolism
- 23 Mar 2019 Results presented in a Sojournix media release.